April 16th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
ATP128 With or Without Ezabenlimab Shows Early Promise in Stage IV Colorectal Cancer
August 1st 2021Preliminary results from the phase 1b KISIMA-01 indicate that combining the single chimeric fusion protein ATP128 with the PD-1 inhibitor, ezabenlimab, is tolerable in patients with heavily pretreated refractory stage IV colorectal cancer and may induce immune responses.
Read More
Pooled Data Suggest Obese Patients With CRC May Benefit From Weight-Based Chemotherapy Doses
July 2nd 2021Findings from the OCTOPUS Consortium of trial data have indicated that obese patients with colorectal cancer have a poorer survival from adjuvant chemotherapy treatment due to reduced treatment dose and average cumulative relative dose.
Read More
New Early-Onset Colon Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use
July 2nd 2021In a first-of-its-kind study, data reveal that unnecessary antibiotic use may increase the risk of colon cancer—especially in people under age 50. Findings were presented at the 2021 World Congress on Gastrointestinal Cancer.
Read More
Second-line treatment with cetuximab in patients with metastatic colorectal cancer given after irinotecan or oxaliplatin-based regimen failure, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.
Read More
Panitumumab Maintenance Combination Prolongs PFS in RAS Wild-Type mCRC
June 8th 2021In the phase 2 PANAMA trial, adding panitumumab to 5-fluorouracil and leucovorin showed significant improvement in progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.
Read More
Trastuzumab Deruxtecan Sustains Efficacy Benefit in HER2-Positive mCRC
June 8th 2021With addition 16-month follow-up, the benefit of fam-trastuzumab deruxtecan-nxki as treatment of patients with HER2-overexpressing metastatic colorectal cancer showed results that were consistent with the primary analysis of the DESTINY-CRC01 trial study.
Read More
USPSTF Lowers Recommended Age for CRC Screenings, Requiring Insurance Coverage for Young Patients
May 18th 2021The United States Preventive Services Task Force is recommending that individuals at average risk of colorectal cancer begin screening exams at age 45 rather than 50 years of age due to the risk of early on-set colorectal cancer.
Read More
Triplet Therapy Is Active and Safe in MSH mCRC
April 24th 2021The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity and a consistent safety profile in patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild type, according to findings from the phase 2 LCCC1632 study.
Read More
Texas Colon & Rectal Specialists Join Texas Oncology and The US Oncology Network
April 2nd 2021Surgical oncology expertise has been expanded to local communities in North Texas after physicians from Texas Colon & Rectal Specialists, a large colorectal cancer practice in North Texas, have joined Texas Oncology, increasing The US Oncology Network’s reach.
Read More
FDA Feedback Leads to Discontinuation of Tesetaxel Development in Solid Tumors
March 23rd 2021Clinical development of the oral chemotherapy agent, tesetaxel is being discontinued as the treatment of metastatic breast cancer, colorectal cancer, and other solid tumors after the FDA provided feedback on a pre-New Drug Application.
Read More
Kentucky Programs Boost CRC Screening Access for Uninsured, Underinsured
March 15th 2021Undergoing colorectal screening can be a challenge for people who don’t have insurance or are underinsured, so the Colon Cancer Prevention Project was created in Kentucky to help establish programs to improve access to screening, including the Kentucky Colon Cancer Screening and Prevention Program.
Read More
Medicaid Grants Coverage of Blood-Based Biomarker Testing in CRC Despite Lack of an Assay
February 25th 2021The Centers for Medicare & Medicaid Services have found that there is sufficient evidence for the coverage of blood-based biomarker tests to be granted for patients with colorectal cancer once every 3 years or at a specific individual test interval labeled by the FDA.
Read More
Pre-Emptive Treatment May Be Superior to Reactive Treatment of Hand–Foot Reactions in mCRC
February 25th 2021A preplanned analysis of the Regorafenib Dose Optimization Study in patients with metastatic colorectal cancer showed using pre-emptive clobetasol to treat hand–foot skin reactions was more effective than treating this adverse event reactively.
Read More
Napabucasin/FOLFIRI Shows No Benefit in OS for Patients With mCRC
February 11th 2021The addition of napabucasin to the FOLFIRI regimen with or without bevacizumab did not demonstrate improvement in overall survival when given as treatment of patients with metastatic colorectal cancer, missing the primary end point of the phase 3 CanStem303C study.
Read More